These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 8819457)

  • 1. Needle exchange programmes should do more to prevent transmission of hepatitis C virus.
    Ford C
    BMJ; 1996 Sep; 313(7059):752. PubMed ID: 8819457
    [No Abstract]   [Full Text] [Related]  

  • 2. Preventing hepatitis C virus transmission in Australians who inject drugs.
    Watson KJ
    Med J Aust; 2000 Jan; 172(2):55-6. PubMed ID: 10738472
    [No Abstract]   [Full Text] [Related]  

  • 3. Injecting drug use in Australia: needle/syringe programs prove their worth, but hepatitis C still on the increase.
    Law MG; Batey RG
    Med J Aust; 2003 Mar; 178(5):197-8. PubMed ID: 12603178
    [No Abstract]   [Full Text] [Related]  

  • 4. Injecting drug use in Australia: needle/syringe programs prove their worth, but hepatitis C still on the increase.
    Copeman M
    Med J Aust; 2003 Jul; 179(2):119; author reply 119. PubMed ID: 12864712
    [No Abstract]   [Full Text] [Related]  

  • 5. Who: four ways to reduce hepatitis infections in people who inject drugs.
    Cent Eur J Public Health; 2012 Sep; 20(3):207. PubMed ID: 23285521
    [No Abstract]   [Full Text] [Related]  

  • 6. The force of numbers: why hepatitis C is spreading among Australian injecting drug users while HIV is not.
    Sullivan LG
    Med J Aust; 1999 Aug; 171(3):165-6. PubMed ID: 10474613
    [No Abstract]   [Full Text] [Related]  

  • 7. Hepatitis C screening and management practices: a survey of drug treatment and syringe exchange programs in New York City.
    Pratt CC; Paone D; Carter RJ; Layton MC
    Am J Public Health; 2002 Aug; 92(8):1254-6. PubMed ID: 12144980
    [No Abstract]   [Full Text] [Related]  

  • 8. Hepatitis C infection among injecting drug users in Scotland: stemming the flow.
    Goldberg D; Taylor A; Hutchinson S; McMenamin J
    Scott Med J; 2000 Oct; 45(5):131-2. PubMed ID: 11130293
    [No Abstract]   [Full Text] [Related]  

  • 9. Changes in injection risk behavior associated with participation in the Seattle needle-exchange program.
    Hagan H; Thiede H
    J Urban Health; 2000 Sep; 77(3):369-82. PubMed ID: 10976611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews.
    Palmateer N; Kimber J; Hickman M; Hutchinson S; Rhodes T; Goldberg D
    Addiction; 2010 May; 105(5):844-59. PubMed ID: 20219055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C prevention and true harm reduction.
    Madden A; Cavalieri W
    Int J Drug Policy; 2007 Oct; 18(5):335-7. PubMed ID: 17854719
    [No Abstract]   [Full Text] [Related]  

  • 12. Human immunodeficiency virus and hepatitis C virus testing services at syringe exchange programs: availability and outcomes.
    Heinzerling KG; Kral AH; Flynn NM; Anderson RL; Scott A; Gilbert ML; Asch SM; Bluthenthal RN
    J Subst Abuse Treat; 2007 Jun; 32(4):423-9. PubMed ID: 17481466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tackling hepatitis C: a tale of two countries.
    Morris K
    Lancet; 2011 Apr; 377(9773):1227-8. PubMed ID: 21495219
    [No Abstract]   [Full Text] [Related]  

  • 14. [Prevention of hepatitis C. How to update the pioneer work done by Eugène Jamot?].
    Coton T
    Presse Med; 2003 Sep; 32(29):1349-50. PubMed ID: 14534495
    [No Abstract]   [Full Text] [Related]  

  • 15. Health effects of prisons. Risks of syringe exchange programmes in prisons prevail.
    Langkamp H
    BMJ; 2000 Dec; 321(7273):1406-7. PubMed ID: 11099292
    [No Abstract]   [Full Text] [Related]  

  • 16. Incarceration and infection: drug policy in the USA.
    Burki T
    Lancet Infect Dis; 2017 Jul; 17(7):697. PubMed ID: 28737490
    [No Abstract]   [Full Text] [Related]  

  • 17. Science versus politics: the need for supervised injection facilities in Montreal, Canada.
    Jozaghi E
    Int J Drug Policy; 2012 Sep; 23(5):420-1. PubMed ID: 22818890
    [No Abstract]   [Full Text] [Related]  

  • 18. Commentary on Turner et al. (2011): Significant global scale-up of harm reduction interventions and pragmatic research approaches needed to prevent hepatitis C transmission.
    Day C; Topp L
    Addiction; 2011 Nov; 106(11):1989-90. PubMed ID: 21978311
    [No Abstract]   [Full Text] [Related]  

  • 19. Why New Jersey needs to change its syringe access laws.
    Roberts JJ
    N J Med; 2004 Nov; 101(11):35-6. PubMed ID: 15605798
    [No Abstract]   [Full Text] [Related]  

  • 20. Needle exchange programs for the prevention of hepatitis C virus infection in people who inject drugs: a systematic review with meta-analysis.
    Davis SM; Daily S; Kristjansson AL; Kelley GA; Zullig K; Baus A; Davidov D; Fisher M
    Harm Reduct J; 2017 May; 14(1):25. PubMed ID: 28514954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.